Work

Phase 2 trial of tucatinib plus trastuzumab deruxtecan in patients with HER2+ locally advanced or metastatic breast cancer with and without brain metastases (HER2CLIMB-04, trial in progress).

Year: 2022

Type: conference-abstract

Source: Journal of Clinical Oncology

DOI: 10.1200/jco.2022.40.16_suppl.tps1111

Authors: Ian E. Krop, Lisa A. Carey, Jorge Ramos, Yiyi Chen, Erika P. Hamilton

Institutions: Dana-Farber Cancer Institute, UNC Lineberger Comprehensive Cancer Center, Seagen (United States), Sarah Cannon, Tennessee Oncology

Language: English

Topic: HER2/EGFR in Cancer Research

Subfield: Oncology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W4281632287

Cites:

Cited by: 5

Related to: 10